Breast cancer · 48 regimens
Cost vs Efficacy
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
AC-THP (Docetaxel, Phesgo) Variant #01 | ERBB2 | R 111 482 | 21d | — | — | ~4 | ~R 172 395 indirect | — |
ddAC-THP (Paclitaxel, Phesgo) Variant #01 | ERBB2 | R 108 125 | 21d | — | — | ~4 | ~R 168 703 indirect | — |
CP-EC and Pembrolizumab Variant #01 | TNBC | R 87 755 | 21d | — | — | ~8 | ~R 678 968 indirect | — |
FEC-THP (Docetaxel) Variant #03 | ERBB2 | R 86 349 | 21d | — | — | ~17 | ~R 515 045 PFS proxy · indirect | 1 |
CP-AC and Pembrolizumab Variant #01 | TNBC | R 86 199 | 21d | — | — | ~8 | ~R 672 744 indirect | — |
AC-THP (Docetaxel) Variant #01 | ERBB2 | R 84 072 | 21d | — | — | ~17 | ~R 505 937 PFS proxy · indirect | 1 |
ddAC-THP (Paclitaxel) Variant #01 | ERBB2 | R 80 714 | 21d | — | — | ~17 | ~R 505 165 PFS proxy · indirect | 1 |
D-FEC+Bev Variant #01 | — | R 65 404 | 21d | — | — | ~3 | ~R 136 240 indirect | — |
nP-ddAC and Atezolizumab Variant #01 | TNBC | R 62 757 | 14d | — | — | 10 | R 462 512 PFS proxy | 1 |
Neratinib and Paclitaxel, then ddAC Variant #01 | ERBB2 | R 60 624 | 21d | — | — | ~4 | ~R 242 497 indirect | — |
Neratinib and Paclitaxel, then AC Variant #01 | ERBB2 | R 60 624 | 21d | — | — | ~4 | ~R 242 497 indirect | — |
AC-THL (Paclitaxel) Variant #01 | ERBB2 | R 58 935 | 28d | — | — | ~4 | ~R 160 759 indirect | — |
nP-ddAC Variant #01 | TNBC | R 40 878 | 14d | — | — | 6 | R 243 730 PFS proxy | 1 |
EC-D and Bevacizumab Variant #01 | TNBC | R 35 234 | 21d | — | — | ~8 | ~R 260 881 indirect | — |
AC-TL (Paclitaxel) Variant #01 | ERBB2 | R 34 004 | 28d | — | — | ~4 | ~R 136 015 indirect | — |
D-AC+Bev Variant #01 | — | R 33 029 | 21d | — | — | ~6 | ~R 192 087 indirect | — |
TH-FEC and H (Paclitaxel) Variant #01 | ERBB2 | R 31 871 | 21d | — | — | ~7 | ~R 127 483 indirect | — |
TH-ddAC (Paclitaxel) Variant #01 | ERBB2 | R 30 724 | 21d | — | — | ~4 | ~R 66 660 indirect | — |
TH-AC (Paclitaxel) Variant #01 | ERBB2 | R 30 724 | 21d | — | — | ~4 | ~R 66 660 indirect | — |
ECH-TH (Docetaxel) Variant #01 | ERBB2 | R 23 993 | 21d | — | — | ~4 | ~R 63 168 indirect | — |
nP-EC Variant #01 | — | R 22 380 | 21d | — | — | ~12 | ~R 249 955 indirect | — |
nP-ddEC Variant #01 | — | R 22 380 | 14d | — | — | ~8 | ~R 169 738 indirect | — |
EC-TH (Docetaxel) Variant #01 | ERBB2 | R 19 922 | 21d | — | — | ~17 | ~R 109 568 PFS proxy · indirect | 1 |
FEC-TH (Paclitaxel) Variant #01 | ERBB2 | R 18 917 | 21d | — | — | ~17 | ~R 105 449 PFS proxy · indirect | 1 |
TH-FEC and H (Docetaxel) Variant #01 | ERBB2 | R 18 329 | 21d | — | — | ~7 | ~R 59 258 indirect | — |
AC-TH (Paclitaxel) Variant #01 | ERBB2 | R 16 640 | 21d | — | — | ~17 | ~R 99 363 PFS proxy · indirect | 3 |
CP-EC Variant #01 | TNBC | R 5 768 | 21d | — | — | ~4 | ~R 23 071 indirect | — |
D-FEC Variant #01 | — | R 5 432 | 21d | — | — | ~3 | ~R 16 295 PFS proxy · indirect | 1 |
FEC-D Variant #01 | — | R 5 432 | 21d | — | ~29.0 mo | ~3 | ~R 16 295 PFS proxy · indirect | 1 |
EC-D Variant #01 | — | R 5 248 | 21d | — | — | ~3 | ~R 15 743 PFS proxy · indirect | 1 |
EC-D Variant #01 | TNBC | R 5 248 | 21d | — | — | ~3 | ~R 15 743 PFS proxy · indirect | 1 |
TH-FEC and H (Docetaxel, SC Trastuzumab) Variant #01 Partial | ERBB2 | R 4 270 | 21d | — | — | ~8 | ~R 17 082 indirect | — |
CP-AC Variant #01 | TNBC | R 4 212 | 21d | — | — | ~4 | ~R 16 846 indirect | — |
T-FAC Variant #01 | — | R 4 099 | 21d | — | — | ~4 | ~R 16 396 indirect | — |
CP-ddAC Variant #01 | TNBC | R 3 944 | 21d | — | — | ~4 | ~R 15 776 indirect | — |
AC-D Variant #01 | — | R 3 692 | 21d | — | — | ~4 | ~R 14 767 PFS proxy · indirect | 2 |
EC-ddT Variant #01 | — | R 3 633 | 21d | — | — | ~4 | ~R 14 534 indirect | — |
ddT-ddEC Variant #01 | — | R 3 633 | 14d | — | — | ~4 | ~R 14 534 indirect | — |
ddT-EC Variant #01 | — | R 3 633 | 21d | — | — | ~4 | ~R 14 534 indirect | — |
T-FEC Variant #01 | — | R 3 122 | 21d | — | — | ~12 | ~R 17 385 indirect | — |
T-FEC Variant #01 | ERBB2 | R 3 122 | 21d | — | — | ~12 | ~R 17 385 indirect | — |
D-AC Variant #01 | — | R 3 042 | 21d | — | — | ~4 | ~R 12 170 indirect | — |
T-EC Variant #01 | — | R 2 938 | 28d | — | — | ~12 | ~R 16 649 indirect | — |
EC-T Variant #01 | — | R 2 554 | 21d | — | — | ~12 | ~R 15 113 PFS proxy · indirect | 2 |
AC-T Variant #01 | — | R 2 077 | 21d | — | — | ~4 | ~R 8 309 PFS proxy · indirect | 2 |
T-AC Variant #01 | TNBC | R 1 382 | 21d | — | — | ~12 | ~R 10 425 indirect | — |
T-ddAC Variant #01 | TNBC | R 1 382 | 14d | — | — | ~12 | ~R 10 425 indirect | — |
T-AC Variant #01 | — | R 1 382 | 21d | — | — | ~12 | ~R 10 425 indirect | — |
48 of 48 regimens shown